CYTEK BIOSCIENCES DL-001
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhan… Read more
Market Cap & Net Worth: CYTEK BIOSCIENCES DL-001 (8EQ)
CYTEK BIOSCIENCES DL-001 (F:8EQ) has a market capitalization of $451.50 Million (€439.86 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #11899 globally and #1272 in its home market, demonstrating a -6.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CYTEK BIOSCIENCES DL-001's stock price €3.44 by its total outstanding shares 127864830 (127.86 Million).
CYTEK BIOSCIENCES DL-001 Market Cap History: 2021 to 2026
CYTEK BIOSCIENCES DL-001's market capitalization history from 2021 to 2026. Data shows change from $1.97 Billion to $451.50 Million (-32.08% CAGR).
CYTEK BIOSCIENCES DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CYTEK BIOSCIENCES DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8EQ by Market Capitalization
Companies near CYTEK BIOSCIENCES DL-001 in the global market cap rankings as of March 18, 2026.
Key companies related to CYTEK BIOSCIENCES DL-001 by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
CYTEK BIOSCIENCES DL-001 Historical Marketcap From 2021 to 2026
Between 2021 and today, CYTEK BIOSCIENCES DL-001's market cap moved from $1.97 Billion to $ 451.50 Million, with a yearly change of -32.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €451.50 Million | -18.10% |
| 2025 | €551.25 Million | -30.58% |
| 2024 | €794.06 Million | +77.94% |
| 2023 | €446.25 Million | -64.21% |
| 2022 | €1.25 Billion | -36.67% |
| 2021 | €1.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CYTEK BIOSCIENCES DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $451.50 Million USD |
| MoneyControl | $451.50 Million USD |
| MarketWatch | $451.50 Million USD |
| marketcap.company | $451.50 Million USD |
| Reuters | $451.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.